SinoMab BioScience EV/EBITDA
Qual é o EV/EBITDA de SinoMab BioScience?
O EV/EBITDA de SinoMab BioScience Limited é N/A
Qual é a definição de EV/EBITDA?
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de empresas na Setor Health Care em HKSE em comparação com SinoMab BioScience
O que SinoMab BioScience faz?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Empresas com ev/ebitda semelhantes a SinoMab BioScience
- Novavax tem EV/EBITDA de N/A
- Cazaly Resources tem EV/EBITDA de N/A
- DC Acquisition tem EV/EBITDA de N/A
- Macarthur Minerals tem EV/EBITDA de N/A
- Sierra Madre Gold and Silver tem EV/EBITDA de N/A
- Rathdowney Resources tem EV/EBITDA de N/A
- SinoMab BioScience tem EV/EBITDA de N/A
- Big Dougie Capital tem EV/EBITDA de N/A
- Income Trust tem EV/EBITDA de N/A
- Aloro Mining tem EV/EBITDA de N/A
- Manganese X tem EV/EBITDA de N/A
- Coho Collective Kitchens tem EV/EBITDA de N/A
- Viva Gold tem EV/EBITDA de N/A